Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood particle test may predict liver failure and cancer risk

NCT ID NCT07185360

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at tiny particles in the blood, called extracellular vesicles, to see if they can predict serious liver problems like liver failure or liver cancer. Researchers will collect blood samples from 845 people, including healthy volunteers, diabetes patients, and those with liver disease, and track their health over time. The goal is to develop simple tests that help doctors decide who needs closer monitoring or early treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to simple blood tests that predict liver disease worsening or liver cancer, helping doctors monitor patients more effectively.
What could go wrong
This is an observational study, not a treatment trial. The tests may not prove accurate enough for routine use, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 845 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Volunteers without liver disease \- Inclusion criteria: Major Exclusion Criteria: * Known liver disease * Active cancer * Viral or bacterial infection within 2 weeks of inclusion (respiratory, dermatological, urinary, digestive, etc.) * Transfusion in the month preceding inclusion * Current participation or less than 3 months' participation in a therapeutic interventional trial * Absence of signed informed consent * Not affiliated to a social security scheme * Pregnant women * Person under guardianship or trusteeship Diabetic patients with F3/F4 fibrosis recruited and followed prospectively Inclusion criteria: * Patient aged 18 or over * Type 2 diabetic (ADA/WHO criteria recalled in section 20.5) * Hepatic fibrosis stage F3/F4 on liver biopsy or hepatic elasticity \> 10 kPa Exclusion criteria: Vulnerable person: a person deprived of liberty by a judicial or administrative decision, or under psychiatric care, and a person admitted to a health or social institution for purposes other than research. * Protected adult * Not affiliated to or not benefiting from a social security scheme * Pregnant or breast-feeding women * Absence of signed informed consent * Illness linked to other etiologies: * Alcoholic liver disease * Current hepatitis B virus infection * Current hepatitis C virus infection * Autoimmune hepatitis according to according to AASLD and EASL recommended criteria * Transferrin saturation \>50% * Alpha antitrypsin ZZ or SZ type deficiency * Wilson's disease * Liver transplant patients * Ultrasound obstruction of blood vessels or bile ducts (on routine ultrasound). If nothing is mentioned on the report, it is considered that there is no obstruction of the blood vessels or bile ducts). * Current participation or less than 3 months' participation in a therapeutic interventional trial Patients with liver disease : Inclusion criteria: * Major * Child-Pugh A, B or C cirrhosis, diagnosed on the basis of histological evidence or liver elasticity \> 15 kPa or a combination of biological and radiological signs. Exclusion criteria: * Presence of one of the following diseases in the 15 days prior to inclusion: acute renal failure, bacterial infection (proven or suspected on clinico-biological criteria), digestive bleeding, * alcoholic hepatitis in the month prior to inclusion * Previous porto-systemic shunt, liver transplantation, primary sclerosing cholangitis, primary biliary cholangitis, Budd-Chiari syndrome * Active or past hepatocellular carcinoma * Active extrahepatic neoplasia, * Current participation or less than 3 months' participation in a therapeutic interventional trial * Absence of signed informed consent * Non affiliation to a social security scheme * Pregnant or breast-feeding * Person under guardianship or trusteeship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bichat Hospital, Beaujon Hospital, Cochin Hospital and Lariboisière Hospital

    Paris, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.